BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33526918)

  • 1. Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease.
    Ruben CL; Pirsl F; Steinberg SM; Holtzman NG; Parsons-Wandell L; Baruffaldi J; Curtis LM; Mitchell SA; Kerep AZ; Cowen EW; Berger A; Joe GO; Datiles MB; Mays JW; Pavletic SZ
    Bone Marrow Transplant; 2021 Jul; 56(7):1584-1592. PubMed ID: 33526918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
    Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
    Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
    Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.
    Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Auletta JJ; Badawy SM; Bhatt N; Bhatt VR; Cahn JY; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Gale RP; Hashem H; Hashmi S; Hematti P; Hong S; Hossain NM; Inamoto Y; Lekakis LJ; Modi D; Patel S; Sharma A; Solomon S; Couriel DR
    Transplant Cell Ther; 2022 Oct; 28(10):712.e1-712.e8. PubMed ID: 35863740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRPα Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies.
    Saliba RM; Srour SA; Greenbaum U; Ma Q; Carmazzi Y; Moller M; Wood J; Ciurea SO; Kongtim P; Rondon G; Li D; Saengboon S; Alousi AM; Rezvani K; Shpall EJ; Cao K; Champlin RE; Zou J
    Front Immunol; 2022; 13():904718. PubMed ID: 35874659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
    Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
    Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
    Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
    Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation].
    Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470
    [No Abstract]   [Full Text] [Related]  

  • 9. Subsequent Cancers in Patients Affected with Moderate or Severe Chronic Graft-versus-Host Disease.
    Schaar DA; Pirsl F; Holtzman N; Steinberg SM; Nashed J; Ruben C; Cowen EW; Mays JW; Mitchell S; Ostojic A; Munshi PN; Joe GO; Comis LE; Morton L; Pavletic SZ
    Transplant Cell Ther; 2021 Nov; 27(11):937.e1-937.e7. PubMed ID: 34380090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular Chronic Graft-versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes after Allogeneic Hematopoietic Cell Transplantation.
    Jeppesen H; Gjærde LK; Lindegaard J; Julian HO; Heegaard S; Sengeløv H
    Transplant Cell Ther; 2022 Dec; 28(12):833.e1-833.e7. PubMed ID: 36002105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
    Yu ZP; Ding JH; Chen BA; Wu F; Gao C; Sun YY; Chen J; Zhao G; Wang J; Li YF; Ding BH; Qian J
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):283-6. PubMed ID: 21575500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
    Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
    Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease.
    Ljubas Kelecic D; Lelas A; Karas I; Desnica L; Vukic T; Sabol I; Vranesic Bender D; Serventi Seiwerth R; Peric Z; Durakovic N; Vitali Cepo D; Vrhovac R; Nemet D; Pavletic S; Pulanic D; Krznaric Z
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):2967-2978. PubMed ID: 32507973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease.
    Novitzky-Basso I; Schain F; Batyrbekova N; Webb T; Remberger M; Keating A; Mattsson J
    PLoS One; 2023; 18(3):e0282753. PubMed ID: 36893113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia.
    Boyiadzis M; Arora M; Klein JP; Hassebroek A; Hemmer M; Urbano-Ispizua A; Antin JH; Bolwell BJ; Cahn JY; Cairo MS; Cutler CS; Flowers ME; Gale RP; Herzig R; Isola LM; Jacobsohn DA; Jagasia MH; Klumpp TR; Lee SJ; Petersdorf EW; Santarone S; Spellman SR; Schouten HC; Verdonck LF; Wingard JR; Weisdorf DJ; Horowitz MM; Pavletic SZ
    Clin Cancer Res; 2015 May; 21(9):2020-8. PubMed ID: 25348512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies: A Single-center Study].
    Lu JP; Wen SP; Wang FX; Li SH; Niu ZY; Wang Y; Zhou ZW; Xu Z; Wang ZZ; Zhang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1238-1243. PubMed ID: 35981391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
    Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
    Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
    Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.